CD73: Combating Tumor Immunosuppression by Targeting Adenosine

Adenosine acts primarily through A2A and A2B receptors, which are expressed on immune cells. Upon binding to these receptors, adenosine activates signaling pathways that lead to:

• Suppression of T cell proliferation and function: Adenosine inhibits CD8+ cytotoxic T lymphocytes, which are essential for killing cancer cells.
• Reduced NK cell activity: NK cells, critical in recognizing and eliminating tumor cells, are suppressed by adenosine, reducing their cytotoxicity.
• Promotion of regulatory T cell (Treg) activity: Adenosine enhances the activity of Tregs, which further suppress effector immune cells, contributing to tumor immune evasion.
• Inhibition of dendritic cells: Adenosine also inhibits the ability of dendritic cells to present antigens and activate T cells, further impairing the immune response.

By fostering a highly immunosuppressive environment, CD73-generated adenosine plays a key role in the development of resistance to immunotherapies, including checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 antibodies.

CD73 is frequently overexpressed in a variety of tumors, and its expression is associated with poor prognosis in many cancer types, including:

• Breast cancer
• Lung cancer
• Colorectal cancer
• Ovarian cancer
• Melanoma

The overexpression of CD73 in these tumors not only enhances adenosine production but also helps tumors escape immune detection by shutting down anti-tumor immune responses. Tumors with high CD73 expression are often more resistant to conventional treatments and show poorer outcomes when treated with checkpoint inhibitors alone.

Targeting CD73 has emerged as a promising therapeutic strategy to break tumor-induced immunosuppression. By inhibiting CD73, therapies can reduce adenosine levels in the tumor microenvironment, thereby:

• Restoring immune function: Inhibiting CD73 allows T cells, NK cells, and other
  immune cells to regain their ability to attack and destroy tumor cells.
• Enhancing the effectiveness of existing immunotherapies: CD73 blockade can synergize with checkpoint inhibitors (like anti-PD-1 and anti-CTLA-4) by reducing immunosuppressive signals, enabling these therapies to work more effectively.
• Reducing tumor growth and metastasis: Targeting CD73 disrupts tumor-promoting mechanisms like immune evasion and metastasis, making tumors more vulnerable to immune destruction.

TY/23 is a monoclonal antibody that binds specifically to CD73 on tumor cells and immune cells, blocking its enzymatic activity and preventing the conversion of AMP into adenosine. This leads to a reduction in adenosine levels within the tumor microenvironment, restoring the anti-tumor immune response. The mechanism of TY/23 can be summarized as follows:

1. Inhibition of CD73 enzymatic activity: TY/23 binds to CD73, blocking its ability to convert AMP into adenosine.
2. Reduction of adenosine levels: By inhibiting CD73, TY/23 reduces the production of adenosine, leading to lower levels of immunosuppressive signals in the tumor microenvironment.
3. Restoration of immune function: With adenosine levels reduced, immune cells such as T cells and NK cells can resume their cytotoxic functions and attack tumor cells.
4. Synergy with checkpoint inhibitors: TY/23 enhances the effectiveness of checkpoint inhibitors by removing adenosine-mediated suppression, allowing therapies like anti-PD-1 and anti-CTLA-4 to achieve greater tumor control.

TY/23 and other CD73-targeting therapies are being explored in a range of cancers, particularly those where adenosine-driven immunosuppression plays a major role. Early clinical studies have shown that CD73 blockade can enhance tumor regression and improve survival, especially in combination with other immunotherapies.

The ability of TY/23 to restore immune surveillance by blocking CD73-mediated immunosuppression is a critical component of its therapeutic potential. Additionally, combining TY/23 with standard immunotherapies, such as anti-PD-1, may provide superior outcomes compared to monotherapies, particularly in cancers where adenosine plays a key role in tumor progression.

One of the most promising aspects of CD73 blockade is its ability to synergize with other forms of immunotherapy, particularly checkpoint inhibitors. While checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 have revolutionized cancer treatment, their effectiveness can be limited by the presence of immunosuppressive factors like adenosine in the tumor microenvironment.

By reducing adenosine levels, CD73 blockade helps to:

• Amplify the immune response: Removing adenosine-mediated suppression allows checkpoint inhibitors to activate T cells more effectively, resulting in a stronger and more sustained anti-tumor immune response.
• Overcome resistance: Tumors that have developed resistance to checkpoint inhibitors may be
  sensitized to treatment when combined with CD73-targeting agents like TY/23.

CD73 inhibition is also being explored in combination with chemotherapy and radiotherapy. Both of these treatments can lead to the release of ATP from dying tumor cells, which is then converted into adenosine by CD73. Blocking CD73 in this context can prevent the formation of immunosuppressive adenosine, enhancing the immune-stimulatory effects of these treatments.

Like other immune-targeting therapies, CD73 inhibition can lead to immune-related adverse events (irAEs). These may include inflammatory responses in tissues where CD73 plays a role in maintaining normal immune tolerance, such as the gastrointestinal tract and lungs. Future clinical trials will focus on optimizing dosing regimens and identifying biomarkers to predict which patients are most likely to benefit from CD73 blockade while minimizing the risk of irAEs.

Although CD73 blockade holds great promise, some tumors may develop resistance to treatment by upregulating other immunosuppressive pathways. In such cases, combination strategies that target multiple immune checkpoints, or therapies that simultaneously inhibit CD73 and other suppressive molecules like CD39, may be necessary to achieve long-lasting tumor control.

CD73 plays a pivotal role in creating an immunosuppressive tumor microenvironment by generating adenosine, which shuts down anti-tumor immune responses. Targeting CD73 with therapies like TY/23 offers a novel approach to restore immune function and enhance tumor destruction. By reducing adenosine levels, CD73 blockade can synergize with existing immunotherapies, such as checkpoint inhibitors, to provide more effective cancer treatments. As clinical trials continue to explore the potential of CD73-targeted therapies, they are poised to become a key component of next-generation cancer immunotherapy strategies.

1. Allard, B., et al., 2017. Targeting CD73 in cancer immunotherapy. Immunotherapy, 9(10), pp.913-923.


2. Stagg, J., et al., 2011. CD73-deficient mice have increased anti-tumor immunity and are resistant to experimental metastasis. Cancer Research, 71(8), pp.2892-2900.


3. Hatfield, S.M., et al., 2015. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Science Translational Medicine, 7(277), pp.277-229.


4. Beavis, P.A., et al., 2015. CD73: a potent suppressor of antitumor immune responses. Trends in Immunology, 36(5), pp.327-337.


5. Perrot, I., et al., 2019. Blocking the adenosine A2A receptor potentiates CD73 blockade and immune checkpoint inhibition. Cancer Immunology Research, 7(3), pp. 353-367.


6. Antonioli, L., et al., 2013. Targeting purinergic signalling in cancer by inhibiting CD39 and CD73. Trends in Pharmacological Sciences, 34(2), pp.83-94.


7. Jin, D., et al., 2010. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Research, 70(6), pp.2245-2255.


8. Young, A., Ngiow, S.F., et al., 2016. Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and improves survival in mice. Clinical Cancer Research, 22(14), pp. 3836-3844.